Assessed digital twins for variance reduction/sample-size savings in Alzheimer's Phase 2 trial (AAIC 2024 poster

Unlearn.AI builds AI-generated 'digital twins' of clinical-trial patients, formally qualified by the EMA and reviewed positively by the FDA for reducing control-arm size in real trials.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.